News Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Real-time Estimate Cboe BZX 17:25:01 20/10/2026 BST			5-day change	1st Jan Change
25.16 ^USD	+4.59%		+8.74%	+42.40%

09-24	Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading	MT
09-04	Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading	MT

All News

Mentions Relevance

10-14	Zai Lab Limited to Present Data from First Clinical Trial Evaluating ZL 1503, an Il-13/Il-31Ra Bispecific Antibody, for Atopic Diseases	CI
10-14	Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases	BU
09-29	Zai Lab Limited To Present First Global Data From Clinical Trial Evaluating Zocilurtatug Pelitecan As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer	CI
09-29	Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	BU
08-26	Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%	MT
08-17	Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis	BU
08-17	Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis	CI
08-06	Zai Lab Limited, Q2 2026 Earnings Call, Aug 06, 2026
08-06	Zai Lab Shares Rise After Q2 Beat	MT
08-06	Zai Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M	MT
08-06	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Loss of $0.46 per ADS, vs. FactSet Est of $-0.68	MT
08-06	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates	BU
08-03	Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas	MT
08-03	U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)	BU
07-22	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026	BU
06-29	Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing	MT
06-17	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas	AQ
06-16	Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug	MT
06-16	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas	BU
06-09	Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment	MT
06-09	Zai Lab Receives China NMPA Approval For TIVDAK For Treatment Of Recurrent Or Metastatic Cervical Cancer	CI
06-09	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer	BU
05-22	Zai Lab President, COO Josh Smiley to Depart	MT
05-22	Zai Lab Ousts COO Josh Smiley	MT